ATE395052T1 - Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes - Google Patents
Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetesInfo
- Publication number
- ATE395052T1 ATE395052T1 AT04769332T AT04769332T ATE395052T1 AT E395052 T1 ATE395052 T1 AT E395052T1 AT 04769332 T AT04769332 T AT 04769332T AT 04769332 T AT04769332 T AT 04769332T AT E395052 T1 ATE395052 T1 AT E395052T1
- Authority
- AT
- Austria
- Prior art keywords
- diabetes
- treatment
- type
- kit inhibitors
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 abstract 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 abstract 1
- 230000000779 depleting effect Effects 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49508803P | 2003-08-15 | 2003-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE395052T1 true ATE395052T1 (de) | 2008-05-15 |
Family
ID=34193274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04769332T ATE395052T1 (de) | 2003-08-15 | 2004-08-16 | Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070032521A1 (de) |
| EP (1) | EP1653934B1 (de) |
| JP (1) | JP2007502809A (de) |
| AT (1) | ATE395052T1 (de) |
| CA (1) | CA2535242A1 (de) |
| DE (1) | DE602004013792D1 (de) |
| WO (1) | WO2005016323A2 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1415987B1 (de) * | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen |
| EP1604665B1 (de) * | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase-hemmer |
| DE602004017481D1 (de) | 2003-09-22 | 2008-12-11 | Euro Celtique Sa | Zur behandlung von schmerzen geeignete therapeutische mittel |
| PT2017276E (pt) | 2003-09-22 | 2011-04-05 | Euro Celtique Sa | Compostos de fenilcarboxamida úteis para o tratamento da dor |
| WO2005044788A1 (ja) * | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | ウレア誘導体およびその製造方法 |
| JPWO2005063709A1 (ja) * | 2003-12-25 | 2007-07-19 | 日本新薬株式会社 | アミド誘導体及び医薬 |
| ATE428421T1 (de) * | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| SG159561A1 (en) | 2005-05-09 | 2010-03-30 | Achillion Pharmaceuticals Inc | Thiazole compounds and methods of use |
| WO2007015569A1 (ja) * | 2005-08-01 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を予測する方法 |
| EP1925676A4 (de) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | Testverfahren für die wirkung eines vaskularisierungsinhibitors |
| EP1938842A4 (de) * | 2005-09-01 | 2013-01-09 | Eisai R&D Man Co Ltd | Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit verbesserten zerfallseigenschaften |
| CN101316590B (zh) | 2005-11-07 | 2011-08-03 | 卫材R&D管理有限公司 | 血管生成抑制剂和c-kit激酶抑制剂的组合使用 |
| WO2007061127A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
| DE102005062986A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| WO2007136103A1 (ja) * | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
| EP2044939A1 (de) * | 2006-06-29 | 2009-04-08 | Eisai R&D Management Co., Ltd. | Therapeutisches mittel gegen leberfibrose |
| KR101472600B1 (ko) * | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
| EP2081562B1 (de) | 2006-09-20 | 2016-02-24 | The Board of Regents of The University of Texas System | Verfahren zur abgabe von flüchtigen anästhetika für die regionalanästhesie und/oder schmerzlinderung |
| EP2119707B1 (de) * | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Zusammensetzung zur behandlung von nicht differenzierten formen von magenkrebsen |
| US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
| CN103342701B (zh) | 2007-02-13 | 2016-09-21 | Ab科学有限公司 | 作为激酶抑制剂的2-氨基噻唑化合物多晶型及其制备方法 |
| US8183263B2 (en) | 2007-05-22 | 2012-05-22 | Achillion Pharmaceuticals, Inc. | Heteroaryl substituted thiazoles |
| CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
| EP2060565A1 (de) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Neue bifunktionelle Verbindungen die Proteinkinasen und Histonedeacetylasen hemmen |
| WO2009094459A1 (en) | 2008-01-22 | 2009-07-30 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
| US20100324087A1 (en) * | 2008-01-29 | 2010-12-23 | Eisai R&D Management Co., Ltd. | Combined use of angiogenesis inhibitor and taxane |
| US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
| BR112012003592B8 (pt) | 2009-08-19 | 2021-05-25 | Eisai R&D Man Co Ltd | composição farmacêutica contendo derivado de quinolina |
| CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| EP2700403B1 (de) | 2011-04-18 | 2015-11-25 | Eisai R&D Management Co., Ltd. | Therapeutikum für tumor |
| WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| CN105264380B (zh) | 2013-05-14 | 2017-09-05 | 卫材R&D管理有限公司 | 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志 |
| CA2957005C (en) | 2014-08-28 | 2021-10-12 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| SG11201706630UA (en) | 2015-02-25 | 2017-09-28 | Eisai R&D Man Co Ltd | Method for suppressing bitterness of quinoline derivative |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| US20230295088A1 (en) * | 2020-08-12 | 2023-09-21 | University Of Iowa Research Foundation | Insulin sensitizers for the treatment of diabetes mellitus |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US7087608B2 (en) * | 2000-03-03 | 2006-08-08 | Robert Charles Atkins | Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
| DE60316810T2 (de) * | 2002-08-02 | 2008-07-17 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren |
| CA2517308A1 (en) * | 2003-02-27 | 2004-09-10 | Ab Science | Tailored treatment suitable for different forms of mastocytosis |
| WO2004098612A2 (en) * | 2003-05-07 | 2004-11-18 | Ab Science | Calcitriol analogs of uses thereof |
| JP4776537B2 (ja) * | 2003-05-27 | 2011-09-21 | ロベルト・ペール・ヘーガークヴィスト | 糖尿病処置のためのチロシンキナーゼ阻害剤の使用 |
-
2004
- 2004-08-16 CA CA002535242A patent/CA2535242A1/en not_active Abandoned
- 2004-08-16 JP JP2006523710A patent/JP2007502809A/ja active Pending
- 2004-08-16 US US10/567,557 patent/US20070032521A1/en not_active Abandoned
- 2004-08-16 EP EP04769332A patent/EP1653934B1/de not_active Expired - Lifetime
- 2004-08-16 AT AT04769332T patent/ATE395052T1/de not_active IP Right Cessation
- 2004-08-16 WO PCT/IB2004/002934 patent/WO2005016323A2/en not_active Ceased
- 2004-08-16 DE DE602004013792T patent/DE602004013792D1/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2535242A1 (en) | 2005-02-24 |
| EP1653934B1 (de) | 2008-05-14 |
| WO2005016323A2 (en) | 2005-02-24 |
| DE602004013792D1 (de) | 2008-06-26 |
| US20070032521A1 (en) | 2007-02-08 |
| JP2007502809A (ja) | 2007-02-15 |
| EP1653934A2 (de) | 2006-05-10 |
| WO2005016323A3 (en) | 2005-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004013792D1 (de) | Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes | |
| DE69924641D1 (de) | Behandlung von asthma anhand von mek-inhibitoren | |
| ATE404202T1 (de) | Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung | |
| ATE373474T1 (de) | Substituierte 2-aminotetraline zur behandlung von depressionen | |
| MXPA05009694A (es) | Metodos para mejorar la calidad de la piel. | |
| ATE390142T1 (de) | Synergistische zusammensetzung zur behandlung von diabetes mellitus | |
| SE0301886D0 (sv) | New use V | |
| DE60112766D1 (de) | Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen | |
| ATE412646T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
| IL165217A (en) | Pesticidal pyridinecarboxamide derivatives, process for their preparation, pesticidal compositions comprising them and use thereof in the preparation of pesticidal compositions | |
| PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
| DE60216281D1 (de) | Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen | |
| NO20055741L (no) | Nye kjemiske forbindelser | |
| DE60307237D1 (de) | Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten | |
| DE60306546D1 (de) | Entzündungshemmende 3-arylthio-3-thiazolylalkylamine | |
| ATE359283T1 (de) | Substituierte pyrazinonverbindungen zur behandlung von entzündungen | |
| IL165259A (en) | Compounds useful in the treatment of anthrax and inhibiting lethal factor | |
| ATE402699T1 (de) | Verwendung von substituierten pyrazolen zur behandlung von allergien | |
| WO2005102346A3 (en) | Use of c-kit inhibitors for treating fibrosis | |
| DE60323613D1 (de) | Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch | |
| DE60334094D1 (de) | Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden | |
| DE60027127D1 (de) | Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen | |
| MXPA06007007A (es) | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. | |
| DE50111407D1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen | |
| SE0301883D0 (sv) | New use II |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |